FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2032207130> ?p ?o ?g. }

• W2032207130 endingPage "352" @default.
• W2032207130 startingPage "345" @default.
• W2032207130 abstract "Background Aromatase inhibitors have shown increased efficacy compared with tamoxifen in postmenopausal early breast cancer. We aimed to assess the efficacy and safety of anastrozole versus tamoxifen in premenopausal women receiving goserelin for early breast cancer in the neoadjuvant setting. Methods In this phase 3, randomised, double-blind, parallel-group, multicentre study, we enrolled premenopausal women with oestrogen receptor (ER)-positive, HER2-negative, operable breast cancer with WHO performance status of 2 or lower. Patients were randomly assigned (1:1) to receive goserelin 3·6 mg/month plus either anastrozole 1 mg per day and tamoxifen placebo or tamoxifen 20 mg per day and anastrozole placebo for 24 weeks before surgery. Patients were randomised sequentially, stratified by centre, with randomisation codes. All study personnel were masked to study treatment. The primary endpoint was best overall tumour response (complete response or partial response), assessed by callipers, during the 24-week neoadjuvant treatment period for the intention-to-treat population. The primary endpoint was analysed for non-inferiority (with non-inferiority defined as the lower limit of the 95% CI for the difference in overall response rates between groups being 10% or less); in the event of non-inferiority, we assessed the superiority of the anastrozole group versus the tamoxifen group. We included all patients who received study medication at least once in the safety analysis set. We report the primary analysis; treatment will also continue in the adjuvant setting for 5 years. This trial is registered with ClinicalTrials.gov, number NCT00605267. Findings Between Oct 2, 2007, and May 29, 2009, 204 patients were enrolled. 197 patients were randomly assigned to anastrozole (n=98) or tamoxifen (n=99), and 185 patients completed the 24-week neoadjuvant treatment period and had breast surgery (95 in the anastrazole group, 90 in the tamoxifen group). More patients in the anastrozole group had a complete or partial response than did those in the tamoxifen group during 24 weeks of neoadjuvant treatment (anastrozole 70·4% [69 of 98 patients] vs tamoxifen 50·5% [50 of 99 patients]; estimated difference between groups 19·9%, 95% CI 6·5–33·3; p=0·004). Two patients in the anastrozole group had treatment-related grade 3 adverse events (arthralgia and syncope) and so did one patient in the tamoxifen group (depression). One serious adverse event was reported in the anastrozole group (benign neoplasm, not related to treatment), compared with none in the tamoxifen group. Interpretation Given its favourable risk–benefit profile, the combination of anastrozole plus goserelin could represent an alternative neoadjuvant treatment option for premenopausal women with early-stage breast cancer. Funding AstraZeneca." @default.
• W2032207130 created "2016-06-24" @default.
• W2032207130 creator A5008549101 @default.
• W2032207130 creator A5023097678 @default.
• W2032207130 creator A5024576654 @default.
• W2032207130 creator A5035071748 @default.
• W2032207130 creator A5057801765 @default.
• W2032207130 creator A5067189124 @default.
• W2032207130 creator A5070207806 @default.
• W2032207130 creator A5075058234 @default.
• W2032207130 creator A5075853905 @default.
• W2032207130 creator A5085550715 @default.
• W2032207130 creator A5089611935 @default.
• W2032207130 date "2012-04-01" @default.
• W2032207130 modified "2023-10-05" @default.
• W2032207130 title "Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial" @default.
• W2032207130 cites W1453600927 @default.
• W2032207130 cites W1857624176 @default.
• W2032207130 cites W1966987047 @default.
• W2032207130 cites W1983546759 @default.
• W2032207130 cites W1985875128 @default.
• W2032207130 cites W1993707310 @default.
• W2032207130 cites W1993918665 @default.
• W2032207130 cites W2012194655 @default.
• W2032207130 cites W2015473392 @default.
• W2032207130 cites W2018445950 @default.
• W2032207130 cites W2023000053 @default.
• W2032207130 cites W2067515394 @default.
• W2032207130 cites W2080089765 @default.
• W2032207130 cites W2081333800 @default.
• W2032207130 cites W2085481633 @default.
• W2032207130 cites W2088094542 @default.
• W2032207130 cites W2097012684 @default.
• W2032207130 cites W2104919541 @default.
• W2032207130 cites W2111253826 @default.
• W2032207130 cites W2137539267 @default.
• W2032207130 cites W2139023087 @default.
• W2032207130 cites W2139248078 @default.
• W2032207130 cites W2147993322 @default.
• W2032207130 cites W2148096512 @default.
• W2032207130 cites W2148796794 @default.
• W2032207130 cites W2162760540 @default.
• W2032207130 cites W2163988169 @default.
• W2032207130 cites W2165037690 @default.
• W2032207130 cites W2167027232 @default.
• W2032207130 cites W2171458023 @default.
• W2032207130 cites W2244207039 @default.
• W2032207130 cites W2517196908 @default.
• W2032207130 doi "https://doi.org/10.1016/s1470-2045(11)70373-4" @default.
• W2032207130 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22265697" @default.
• W2032207130 hasPublicationYear "2012" @default.
• W2032207130 type Work @default.
• W2032207130 sameAs 2032207130 @default.
• W2032207130 citedByCount "136" @default.
• W2032207130 countsByYear W20322071302012 @default.
• W2032207130 countsByYear W20322071302013 @default.
• W2032207130 countsByYear W20322071302014 @default.
• W2032207130 countsByYear W20322071302015 @default.
• W2032207130 countsByYear W20322071302016 @default.
• W2032207130 countsByYear W20322071302017 @default.
• W2032207130 countsByYear W20322071302018 @default.
• W2032207130 countsByYear W20322071302019 @default.
• W2032207130 countsByYear W20322071302020 @default.
• W2032207130 countsByYear W20322071302021 @default.
• W2032207130 countsByYear W20322071302022 @default.
• W2032207130 countsByYear W20322071302023 @default.
• W2032207130 crossrefType "journal-article" @default.
• W2032207130 hasAuthorship W2032207130A5008549101 @default.
• W2032207130 hasAuthorship W2032207130A5023097678 @default.
• W2032207130 hasAuthorship W2032207130A5024576654 @default.
• W2032207130 hasAuthorship W2032207130A5035071748 @default.
• W2032207130 hasAuthorship W2032207130A5057801765 @default.
• W2032207130 hasAuthorship W2032207130A5067189124 @default.
• W2032207130 hasAuthorship W2032207130A5070207806 @default.
• W2032207130 hasAuthorship W2032207130A5075058234 @default.
• W2032207130 hasAuthorship W2032207130A5075853905 @default.
• W2032207130 hasAuthorship W2032207130A5085550715 @default.
• W2032207130 hasAuthorship W2032207130A5089611935 @default.
• W2032207130 hasConcept C121608353 @default.
• W2032207130 hasConcept C126322002 @default.
• W2032207130 hasConcept C142724271 @default.
• W2032207130 hasConcept C143998085 @default.
• W2032207130 hasConcept C168563851 @default.
• W2032207130 hasConcept C203092338 @default.
• W2032207130 hasConcept C204787440 @default.
• W2032207130 hasConcept C27081682 @default.
• W2032207130 hasConcept C2776067312 @default.
• W2032207130 hasConcept C2776215463 @default.
• W2032207130 hasConcept C2777176818 @default.
• W2032207130 hasConcept C2778043895 @default.
• W2032207130 hasConcept C2778504769 @default.
• W2032207130 hasConcept C2908647359 @default.
• W2032207130 hasConcept C29456083 @default.
• W2032207130 hasConcept C530470458 @default.
• W2032207130 hasConcept C71924100 @default.
• W2032207130 hasConcept C99454951 @default.
• W2032207130 hasConceptScore W2032207130C121608353 @default.
• W2032207130 hasConceptScore W2032207130C126322002 @default.

• next